Haberler C, Slavc I, Czech T, Gelpi E, Heinzl H, Budka H, Urban C, Scarpatetti M, Ebetsberger-Dachs G, Schindler C, Jones N, Klein-Franke A, Maier H, Jauk B, Kiefer A, Hainfellner J A
Institute of Neurology, Medical University of Vienna, Währinger Gürtel 18-20, A-1097 Vienna, Austria.
Eur J Cancer. 2006 Nov;42(17):2996-3003. doi: 10.1016/j.ejca.2006.05.038. Epub 2006 Sep 25.
Standard postoperative treatment of medulloblastoma consists of craniospinal irradiation and chemotherapy. Currently, only clinical factors are used for therapy stratification. To optimise treatment and patient outcome, biological prognostic markers are needed. In the present study we tested the prognostic influence of four histopathological parameters considered in recent publications as prognostic factors in medulloblastoma. We analysed a series of 82 Austrian medulloblastoma patients who were treated according to the consecutive HIT protocols for medulloblastoma conducted by the German Society of Paediatric Haematology and Oncology. Histological subtype and immunohistochemical expression of erbB-2, TRKC, and survivin were determined on paraffin embedded tumour tissue and correlated with patient outcome. Statistical analysis showed a significant correlation of high expression levels of survivin with decreased survival. None of the other investigated histopathological factors correlated significantly with patient outcome. Our data indicate that high survivin expression is related to unfavourable clinical outcome in medulloblastoma patients.
髓母细胞瘤的标准术后治疗包括颅脊髓照射和化疗。目前,仅临床因素用于治疗分层。为了优化治疗和患者预后,需要生物学预后标志物。在本研究中,我们测试了最近出版物中被认为是髓母细胞瘤预后因素的四个组织病理学参数的预后影响。我们分析了82例奥地利髓母细胞瘤患者,这些患者按照德国儿科血液学和肿瘤学会实施的连续HIT髓母细胞瘤方案进行治疗。在石蜡包埋的肿瘤组织上确定组织学亚型以及erbB-2、TRKC和生存素的免疫组化表达,并将其与患者预后相关联。统计分析显示生存素高表达水平与生存率降低显著相关。其他研究的组织病理学因素均与患者预后无显著相关性。我们的数据表明,生存素高表达与髓母细胞瘤患者不良临床预后相关。